Compare · head to head
Myriad Genetics vs National Research
National Research ranks higher overall — 360 rank 43 vs 12.
Myriad Genetics leads on Value (51 vs 37) and Growth (44 vs 29). National Research leads on Quality (75 vs 62), Safety (38 vs 16) and Sentiment (63 vs 30).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Health Care Providers & Services |
| Size | Medium | Small |
| ISIN | US62855J1043 | US6373722023 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 12 | 43 |
| Value | 51 | 37 |
| Quality | 62 | 75 |
| Growth | 44 | 29 |
| Safety | 16 | 38 |
| Sentiment | 30 | 63 |
| Quality details | ||
| Profitability | 56 | 89 |
| Cash Truth | 69 | 61 |
Myriad Genetics vs NateraMyriad Genetics vs Rigel PharmaceuticalsMyriad Genetics vs LifeStance HealthMyriad Genetics vs Kestra Medical TechnologiesAdd a third stock →
Full analyses: Myriad Genetics · National Research
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100